TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pulp Capping With Two Different Agents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Any patient 7 years old or older who requires a direct pulp cap of a permanent tooth.~2. The tooth must exhibit a vital pulp upon exposure.~3. The exposure can be due to mechanical, traumatic or carious causes.~4. Patient will be available for the two year follow-up period.~Exclusion Criteria:~1. Any primary tooth requiring a direct pulp cap.~2. Tooth demonstrates any radicular radiolucency on a radiograph.~3. Tooth exhibits spontaneous pain.~4. Tooth exhibits lingering (more than 5 seconds) pain to temperature or biting stimulus.~5. Non-English and/or non-Spanish speaking subjects.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mineral Trioxide Aggregate (Type: ACTIVE_COMPARATOR): Pulp capping agent, Mineral Trioxide Aggregate used as a direct pulp cap
- Calcium Hydroxide (Type: ACTIVE_COMPARATOR): Pulp capping agent, Calcium Hydroxide used as a direct pulp cap

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Histologically documented squamous cell carcinoma involving either the oral cavity, oropharynx, nasopharynx, hypopharynx, or larynx~* Newly diagnosed, locally advanced stage head and neck cancer (unresectable/unresected disease); American Joint Committee on Cancer \[AJCC\] Stage III, IVA or IVB amenable to radiotherapy with concurrent chemotherapy as the definitive treatment modality~* At least 50 Gray of radiation treatment to areas of the oral cavity/oropharynx mucosa that can be visualized~* Concurrent chemotherapy regimen of Cisplatin 100mg/m\^2 on days 1, 22, and 43~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) less than or equal to 2~* Adequate hematologic, renal and hepatic function~* Negative pregnancy test by serum or urine~* Signed informed consent~Key Exclusion Criteria:~- Presence or history of any other primary malignancy (other than curatively treated in situ cervical cancer, or basal cell carcinoma of the skin without evidence of disease for greater than 3 years)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Palifermin (Type: EXPERIMENTAL): Participants received a single intravenous dose of palifermin at 180 μg/kg three days before the start of radiotherapy, and then 7 once weekly palifermin doses at the same dose level during a 7-week radiotherapy/chemotherapy course.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received a single IV dose of placebo three days before the start of radiotherapy, and then 7 once weekly placebo doses during a 7-week radiotherapy/chemotherapy course.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Capable of understanding and complying with the protocol~* Has a confirmed diagnosis of RRMS~* Neurologically stable with no evidence of relapse within 30 days prior to randomization~* Agrees to use an acceptable method of contraception for the duration of the study and for 30 days after any study drug administration, or is surgically sterile or post-menopausal~Key Exclusion Criteria:~* Have any finding(s) that would compromise the safety of the subject, affect the subject's ability to adhere to the protocol visit schedule or to fulfill visit requirements, or would make the subject unsuitable for participation in the study~* Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS~* History of clinically significant cardiovascular, pulmonary, GI, dermatologic, psychiatric, neurologic (other than MS), endocrine, renal, and/or other major disease that would preclude participation in a clinical trial~* History of GI surgery (except appendectomy that occurred more than 6 months prior to screening~* History of clinically significant recurring or active gastrointestinal symptoms (eg, nausea, diarrhea, dyspepsia, constipation) within 3 months of screening~* Chronic use (7 days) of medical therapy to treat any GI symptoms within 1 month of screening Has a clinically significant medical condition or observed abnormality at screening~* History of a myocardial infarction, including a silent myocardial infarction or unstable angina~* History of clinically significant drug or alcohol abuse within the past year prior to screening~* Clinically significant history of suicidal ideation or suicidal behavior in the last 12 months~* Subject is pregnant or breastfeeding or plans to become pregnant or begin breastfeeding at any point during the study and for 30 days after any study drug administration~* Prior use of Dimethyl Fumarate (DMF)~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ALKS 8700 (Type: EXPERIMENTAL): Oral capsules, administered orally twice daily.
- Dimethyl Fumarate (Type: ACTIVE_COMPARATOR): Oral capsules, administered orally twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Biosynthetic Growth Hormone and/or Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
INCLUSION CRITERIA~All subjects will be outpatients.~Patients must be females with Turner's syndrome diagnosed by leukocyte karyotype~Chronologic age greater than or equal to 5 years.~Prepubertal Tanner I status. If breast development is Tanner II or III, demonstration of castrate status through measurement of serum FSH (greater than 12 MIU/ML).~All patients must be below the 10th percentile for chronologic age.~Patients must have at least 6 months accurate, growth measurements available for calculation of pre-study growth velocity. Pretreatment measurements must be obtained during a time when the patient is not receiving a potential growth-promoting agent.~Patients judged to be thyroxine deficient must have replacement which has resulted in normal thyroid function tests over the three-month period prior to enrollment (T4, T3, Thyroid Stimulating Hormone).~Patients and/or parents or legal guardians of patients must sign an informed consent statement. Assent should be obtained from all patients competent to understand the protocol. Local IRB requirements apply.~EXCLUSION CRITERIA~Patients who have received any form of human growth hormone within the past 3 months, or who have received a cumulative course of therapy totaling greater than one year.~Patients who have received treatment with estrogen or androgen in the past three months or who have received a cumulative course of therapy totaling greater than one year.~Patients who have any Y component in their chromosome analysis.~Patients with a chronologic age greater than 12 years.~Patients with a bone age greater than 12 years.~Patients who have clinically significant cardiac, pulmonary, gastrointestinal, hepatic or renal disease or who have had any malignancy.~Patients who have significant hematuria or proteinuria in pretherapy evaluation.~Patients who have diabetes mellitus.~Patients who have any active chronic infection (tuberculosis).~Patients who are taking amphetamines or any other drugs known to interfere with growth hormone secretion or actions.~Patients who are poor medical, psychological, or psychiatric risks for whom, in the opinion of the principal investigator, the investigational drug would be unwise.~Patients whose parents are substance abusers, nor those who come from homes in which appropriate emotional development may be limited.~Patients who cannot be seen on the schedule required by the protocol.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age greater than or equal to 18 years at the time of signing informed consent~* Body Mass Index (BMI) greater than or equal to 27 kg/m\^2 '~* History of at least one self-reported unsuccessful dietary effort to lose body weight~* Diagnosed with type 2 diabetes (haemoglobin A1c 7-10% (53-86 mmol/mol) (both inclusive)) 180 days or longer prior to the day of screening~Exclusion Criteria:~* A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records~* Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of less than 30 mL/min/1.73 m\^2 (less than 60 ml/min/1.73 m\^2 in subjects treated with Sodium-glucose Cotransporter 2 Inhibitors) according to chronic kidney disease (CKD)-Epidemiology Collaboration (EPI) creatinine equation as defined by Kidney Disease: Improving Global Outcomes (KDIGO) 2012 by the central laboratory at screening~* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a pharmacologically pupil-dilated fundus examination performed by an ophthalmologist or an equally qualified health care provider (e.g. optometrist) within the past 90 days prior to screening or in the period between screening and randomisation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide 1.0 mg (Type: EXPERIMENTAL): Participants will receive semaglutide 1.0 mg and semaglutide placebo I during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
- Semaglutide 2.4 mg (Type: EXPERIMENTAL): Participants will receive semaglutide 2.4 mg and semaglutide placebo II during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
- Semaglutide placebo I/II (Type: PLACEBO_COMPARATOR): Participants will receive semaglutide placebo I and II during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participants ≥ 18 and ≤ 65 years of age~* Documented decreased LAL activity~* Evidence of liver involvement~Exclusion Criteria:~* Clinically significant concurrent disease, serious inter-current illness, concomitant medications or other extenuating circumstances~* Clinically significant abnormal values on laboratory screening tests, other than liver function or lipid panel tests~* Aspartate aminotransferase and/or alanine aminotransferase persistently elevated \> 3x upper limit of normal at screening~* Previous hemopoietic bone marrow or liver transplant~* Current history of alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sebelipase alfa 0.35 mg/kg (Type: EXPERIMENTAL): Cohort 1: Participants were administered once weekly (qw) infusions of 0.35 mg/kg sebelipase alfa.
- Sebelipase alfa 1 mg/kg (Type: EXPERIMENTAL): Cohort 2: Participants were administered qw infusions of 1 mg/kg sebelipase alfa.
- Sebelipase alfa 3 mg/kg (Type: EXPERIMENTAL): Cohort 3: Participants were administered qw infusions of 3 mg/kg sebelipase alfa.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* In good health~* Negative clinical history of varicella, zoster, measles, mumps, rubella, diptheria, tetanus, pertussis, invasive Hib disease and hepatitis B~* Had completed either a 2-dose primary series of PedvaxHIB or COMVAX or any 3-dose primary series of a licensed Hib vaccine~* Had received 2 or 3 doses of any hepatitis B vaccine or COMVAX prior to entry into trial~Exclusion Criteria:~* Previous receipt of measles, mumps, rubella or varicella vaccine either alone or in combination~* Any immune impairment or deficiency~* Recent household, daycare or school exposure to invasive Hib disease or hepatitis B~* Exposure to measles, mumps, rubella, varicella, or zoster in the 4 weeks prior to vaccination~* Vaccination with an inactive vaccine with in the past 14 days~* Vaccination with a live vaccine within the past 30 days~* Receipt of immune globulin, blood transfusion or blood-derived product in the past 3 months~* Recent history of fever or underlying medical problems

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 15 Months
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): ProQuad + Tripedia + Comvax at Day 0 (Concomitant)
- 2 (Type: EXPERIMENTAL): ProQuad at Day 0, Tripedia + Comvax at Day 42(Nonconcomitant)
- 3 (Type: ACTIVE_COMPARATOR): Varivax + M-M-R II at Day 0, Tripedia + Comvax at Day 42 (Control)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants aged greater than or equal to 21 and less than 65 years at the time of obtaining written informed consent~2. Participants diagnosed with primary insomnia based on the Diagnostic and Statistical Manual of Mental Disorders, text revision (DSM-IV-TR) Japanese version and have both of the following conditions which are persistent for more than or equal to 4 weeks before the start of observation period:~   * Sleep latency of more than or equal to 30 minutes for more than or equal to 3 days a week~  * Total sleep time of less than or equal to 390 minutes for more than or equal to 3 days a week~3. Participants who meet both of the following based on polysomnogram (PSG) in observation period:~   * Objective sleep latency of more than or equal to 20 minutes for 2 consecutive PSG days~  * Objective total sleep time of less than or equal to 420 minutes for 2 consecutive PSG days, or objective wake time during sleep of more than or equal to 20 minutes for 2 consecutive PSG days~Exclusion Criteria:~1. Participants with comorbid primary sleep disorders (e.g., circadian rhythm disorder, restless limb syndrome, periodic limb movement disorder, sleep apnea syndrome), other than primary insomnia.~2. Participants with insomnia caused by pharmacological actions (drug-induced insomnia).~3. Participants with comorbid sleep disorder associated with other disease(s) such as psychiatric and/or physical disease(s).~4. Participants with a complication of psychiatric disorders in Axis I or personality disorder in Axis II defined in DSM-IV-TR Japanese version.~5. Participants with organic mental disorder.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Eszopiclone 1 mg (Type: EXPERIMENTAL): None
- Eszopiclone 2 mg (Type: EXPERIMENTAL): None
- Eszopiclone 3 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Zolpidem Tartrate 10 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects must be at least 45 years old at the time of consent.~* Subjects must have a pre-established primary clinical diagnosis of COPD.~* Subjects must have a baseline FEV1 of ≤ 65% of predicted normal value at Visit 1.~* Subjects must have a FEV1 ≥ 0.70L at Visit 1.~* Subjects must have a FEV1/forced vital capacity (FVC) ratio of ≤ 70% at Visit 1.~Exclusion Criteria:~* Subjects who do not have a 15 pack-year smoking history and a baseline breathlessness severity grade of 2 (as measured by the Modified Medical Research Council \[MMRC\] Dyspnea Scale Score) at Screening.~* Subjects with life-threatening/unstable respiratory status, including upper or lower respiratory tract infection, within the previous 30 days prior to Visit

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 15 mcg BID / 30 mcg QD (Type: EXPERIMENTAL): Arformoterol 15 microgram twice a day (BID) taken each morning and evening for one visit followed by Arformoterol 30 microgram once a day (QD) in the morning and placebo in the evening for the next visit.
- 30 mcg QD / 15 mcg BID (Type: EXPERIMENTAL): Arformoterol 30 microgram once a day (QD) in the morning and placebo in the evening for one visit followed by Arformoterol 15 microgram twice a day (BID) in the morning and evening for the next visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Supplemental Oxygen Reduces Surgical Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective colorectal resection,~* Patients having abdominal-peritoneal reconstructions were included, but not those scheduled for minor colon surgery (e.g., polypectomy, isolated colostomy) or laparoscopic surgery.~Exclusion Criteria:~* Exclusion criteria included expected surgery time of less than one hour, fever or existing signs of infection, diabetes mellitus (type I or II), HIV infection, weight loss exceeding 20% in the previous three months, serum albumin concentration \< 30 g/L, and a leukocyte count \<2500 cells/ml.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 80% perioperative oxygen (Type: ACTIVE_COMPARATOR): Perioperative supplemental oxygen: Patients were randomly assigned to 80% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
- 30% perioperative oxygen (Type: PLACEBO_COMPARATOR): Standard oxygen: Patients were randomly assigned to 30% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject completed visit 6 of PGL09-026 study, 10 to 18 days after menstruation following end of treatment with PGL4001, and did not take medications forbidden by the protocol.~Exclusion Criteria:~* Subject has a large uterine polyp (\> 2cm).~* Subject has one or more ovarian cysts ≥ 4cm diagnosed by ultrasound during PGL09-026 study.~* Subject has abnormal hepatic function at re-test.~* Subject has clinically significant abnormal findings at visit A or any other medical condition(s) or laboratory findings that, in the opinion of the investigator, might jeopardize the subject's safety or interfere with study evaluations.~* Subject has a positive pregnancy test or is planning a pregnancy during the course of the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets) during 3 periods each ended by a drug free period until return of menses.
- B (Type: EXPERIMENTAL): PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of progestin (oral tablets) during 3 periods each ended by a drug free period until return of menses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete